Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Prelude Therapeutics
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05665530CT.gov A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Myelomonocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| prt2527 (this asset) | Prelude Therapeutics | P1 | CC · 46 |
| Pevonedistat | Takeda | P3 | BB |
| Venetoclax | Servier Bio-Innovation LLC | P2/3 | BB |
| Idarubicin | Fred Hutchinson Cancer Center | P3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BB |
| Melphalan | City of Hope Medical Center | P2 | BB |
| Azacitidine | The University of Hong Kong | P3 | BB |
| Astx727 | Taiho Oncology, Inc. | P3 | BB |
| Tacrolimus | City of Hope Medical Center | P2 | BB |
+42 more in the Chronic Myelomonocytic Leukemia cohort
Other indications for prt2527
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P1 | CC · 47 |
| Aggressive B-Cell Non-Hodgkin Lymphoma | — | P1 | CC · 47 |
| Richter Transformation | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. prt2527 in Chronic Myelomonocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prt2527-chronic-myelomonocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →